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Abstract
Complement factor H (fH) is a plasma protein that regulates activation of the alternative pathway, and mutations in fH
are associated with a rare form of thrombotic microangiopathy (TMA), known as atypical hemolytic uremic syndrome
(aHUS). A more common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of normal
ADAMTS-13-mediated cleavage of von Willebrand factor (VWF). We investigated whether fH interacts with VWF and
affects cleavage of VWF. We found that factor H binds to VWF in plasma, to plasma-purified VWF, and to
recombinant A1 and A2 domains of VWF as detected by co-immunoprecipitation (co-IP) and surface plasmon
resonance assays. Factor H enhanced ADAMTS-13-mediated cleavage of recombinant VWF-A2 as determined by
quantifying the cleavage products using Western-blotting, enhanced cleavage of a commercially available fragment
of VWF-A2 (FRETS-VWF73) as determined by fluorometric assay, and enhanced cleavage of ultralarge (UL) VWF
under flow conditions as determined by cleavage of VWF-platelet strings attached to histamine stimulated endothelial
cells. Using recombinant full-length and truncated fH molecules, we found that the presence of the C-terminal half of
fH molecule is important for binding to VWF-A2 and for enhancing cleavage of the A2 domain by ADAMTS-13. We
conclude that factor H binds to VWF and may modulate cleavage of VWF by ADAMTS-13.
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Introduction
Factor H (fH) is a plasma protein that negatively regulates
the alternative complement pathway in both fluid phase and on
cell surfaces. It has a molecular mass of 150kD and circulates
in plasma at a concentration of about 500 µg/ml (3 µM). Factor
H prevents propagation of complement activation by promoting
cleavage of C3b by plasma factor I (cofactor activity). Factor H
is composed of 20 homologous structural domains, known as
short consensus repeats (SCR). Despite the structural
similarities between different SCRs, there are functional
distinctions between different regions of fH. The N-terminal
SCRs 1-4 are necessary for cofactor activity [1,2], whereas C-
terminal SCRs 18-20 are responsible for binding of fH to the
cell surface and regulating complement activity on the cell
surface [3,4].
Mutations in the factor H gene are associated with a rare
familial form of thrombotic microangiopathy known as atypical
hemolytic uremic syndrome (aHUS) [5–10]. Most of these
mutations are clustered in the C-terminal SCRs 18-20 of fH and
result in synthesis of abnormal fH [5,9,10]. The mechanism
linking abnormal function of fH to thrombotic microangiopathy
in aHUS is not clear. Many of the mutant fH molecules are
unable to bind to cell surfaces and control complement
activation, resulting in complement-induced endothelial injury
and platelet activation [11,12]. Interestingly, in animal studies, a
total lack of fH was not associated with thrombotic
microangiopathy [13], while expression of a truncated fH
lacking the 5 C-terminal SCRs (SCRs 16-20) generated a
phenotype very similar to that of aHUS [14]. In these transgenic
mice, truncated fH maintained a near normal C3 concentration
in plasma compared to a severely reduced C3 concentration in
fH deficient mice.
Clinical manifestations of aHUS are similar to another
thrombotic microangiopathy known as thrombotic
thrombocytopenic purpura (TTP) which is caused by a
decrease in the function of VWF-cleaving protease
ADAMTS-13 (A Disintegrin And Metalloproteinase with a
ThromboSpondin type 1 motif). Although aHUS is principally a
kidney disorder and TTP is a more systemic disorder, often
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there is not a clear distinction between TTP and aHUS,
especially in younger patients with a relapsing course. In
typical HUS caused by Shiga toxin-producing bacteria the
activity of ADAMTS-13 is within normal range, but there are
few reports showing low activities of ADAMTS-13 in congenital
relapsing HUS [15,16]. This observation raises the possibility of
an etiologic link between aHUS and TTP resulting in clinical
overlap between these two thrombotic microangiopathies. We
hypothesized that fH’s role in the cleavage of VWF might
connect etiologies of TTP and aHUS. We studied the physical
interaction between fH and VWF and mapped the binding site
of VWF on fH and, vice versa. Next we studied the effect of fH
on ADAMTS-13-mediated cleavage of VWF and determined
the region in fH involved in this process.
Experimental Procedures
Reagents
The ADAMTS-13 activity assay kit (Gen-Probe), plasma
purified human factor H and factor I (Complement Technology
Inc.), human factor H cDNA in pCMV6-XL4 vector (OriGene
Technologies Inc.), plasma purified human VWF (Calbiochem),
human VWF cDNA in pcDNA 3.1 vector, human ADAMTS-13
cDNA in pSectag vector (Invitrogen) [17,18], goat anti-human
factor H and C3 (Complement Technology Inc.), monoclonal
anti-human fH (clone 90X, Quidel), rabbit anti-human VWF
(Dako), rabbit anti-GST (Invitrogen), goat anti-ADAMTS-13
(Novus Biologicals) antibodies, control normal goat and rabbit
IgG (Santa Cruz Biotechnology), secondary antibodies
including anti-goat (Bethyl) and anti-rabbit (Amersham
Biosciences), and horseradish peroxidase-conjugated
antibodies were purchased from the indicated sources.
Washed platelets
Whole blood was collected into acid-citrate dextrose (ACD)
anticoagulant (85 mM sodium citrate, 111 mM glucose, and 71
mM citric acid) at a 9: 1 vol/vol ratio, and centrifuged at 150 × g
for 15 min (room temperature) to obtain platelet-rich plasma
(PRP). To isolate platelets, PRP was centrifuged at 900 × g for
10 min, platelet pellets were washed, and resuspended in
Tyrode buffer (138 mM sodium chloride, 5.5 mM glucose, 12
mM sodium bicarbonate, 2.9 mM potassium chloride, and 0.36
mM dibasic sodium phosphate, pH 7.4).
Generating recombinant proteins
Full-length wild type human fH (F4 with SCRs 1-20, amino
acids M1-R1231) and truncated fH (F1 with SCRs 1-5, amino
acids M1-K323; F2 with SCRs 1-10, amino acids M1-E625; and F3
with SCRs 1-15, amino acids M1-G928) were generated by
polymerase chain reaction (PCR) with 5′ primer:
GGACTTTCCAAAATGTCGT, and 3′ primers (F1:
ATCCTCGAGCTTTCAAGGTACATCT, F2:
TTGCTCGAGCCTCTTTACATATTGG, F3:
ACACTCGAGCGCCTTCACACTGAGG, and F4:
ATCCTCGAGCTCTTTTTGCACAAGT), using human fH cDNA
as a template. After confirming their sequence, the amplified
fragments were digested with NotI (5′) and XhoI (3′) and ligated
to pSecTag2B His tag vector (Invitrogen). The plasmids
containing full-length or truncated factor H were transfected
into mammalian HEK 293 cells using micelle carriers
(LipofectamineTM 2000, Invitrogen). Stably transfected HEK 293
cells were maintained in Dulbecco’s Modified Eagle media
containing 10% fetal bovine serum and the selection agent
Hygromycin B (500µg/ml, Invitrogen). ADAMTS-13 cDNA was
cloned into pSecTag2B His-tag vector (Invitrogen) at the HindIII
and XbaI sites, and transfected into HEK 293 cells (Invitrogen)
with Lipofectamine 2000 (Invitrogen). The recombinant proteins
secreted into the serum-free medium were purified on a Ni-
NTA column (Qiagen) and quantified using a BCA protein
assay kit (Pierce).
The DNA sequence encoding the VWF A2 domain (amino
acids P1480-G1672) was PCR amplified from the VWF cDNA
using 5′ primer: ACTGGATCCCCGGGGCTCTTGGGG, and 3′
primer: CAGGAATTCTCCGGAGCAGCACCT, and ligated into
pGEX-2T GST vector (GE Healthcare) or pSecTag2B His-tag
vector. GST-A2 recombinant protein was expressed in E. coli
and purified by chromatography on glutathione agarose beads
(Invitrogen). His-tagged A2 was expressed in HEK 293 cells
and purified by chromatography using Ni-NTA. Plasmids
encoding His-tagged VWF-A1 domain (amino acids Q1238-
D1471), VWF-A2 (amino acids G1481-R1668), and VWF-A3 domain
(amino acids S1671-G1874) [19–21] were transfected to E. coli.
The recombinant VWF-A1, VWF-A2, and VWF-A3 were
purified by chromatography on Ni-NTA. A DNA fragment
encoding the B and C domains of human VWF was amplified
from VWF cDNA, subcloned into the pcDNA3.1/myc-His vector
(Invitrogen), and transfected into HEK 239 cells. Myc-tagged
VWF BC domains (VWF-BC) were purified using monoclonal
Myc antibody (Invitrogen).
Immunoprecipitation and Western blotting
Immunoprecipitations were performed by incubating plasma-
purified factor H (30 and 60 nM) with plasma-purified VWF (20
nM) in the presence of rabbit anti-VWF antibody (10 µl) or
control rabbit IgG. Sepharose-conjugated Protein A/G (20 µl)
was added to each sample, and incubated overnight at 4oC. To
study the association between fH and VWF in serum, 250 µl of
normal serum was incubated with sepharose beads-conjugated
protein A/G (protein A/G beads) for 2 hr at room temperature
and centrifuged at 10,000 × g. The serum supernatant was
incubated with either 10 µg anti-VWF antibody or control rabbit
IgG, and protein A/G beads for another 2 hours. Sepharose-
bead-captured proteins were washed with ice-cold PBS buffer
containing 0.01% Triton-100 (PBS-T), separated by SDS-
polyacrylamide gel electrophoresis (PAGE) under reducing
conditions, transferred to immobilon-P membranes (Millipore),
and detected by a goat anti-Factor H antibody (1:20,000,
overnight at 4oC) and a peroxidase-conjugated rabbit anti-goat
antibodies (1:40,000). Immunoprecipitations were also carried
out by incubating plasma-purified factor H (30 nM) with
recombinant VWF-A1 (100 nM), VWF-A2 (100 nM, purified
from transfected E. coli), VWF-A2 (100 nM, purified from
transfected HEK 293 cells), VWF-A3 (100 nM), or VWF-BC
domains. In another group of experiments, recombinant GST-
VWF-A2 (100 nM) or VWF-A1 (100 nM) was incubated with
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recombinant full-length or truncated fH (F4, F3, F2, or F1,30
nM each). After adding glutathione-conjugated agarose beads
(20 µl) (for samples with GST-VWF-A2) or sepharose beads
coated with polyclonal anti-VWF antibody (for samples with
VWF-A1), each sample was incubated overnight at 4oC, and
washed for three times. The precipitated proteins were
separated by SDS-PAGE under reducing conditions. Proteins
were transferred to membranes, immunoblotted with polyclonal
or monoclonal anti-fH antibody, and visualized by
chemiluminescence. The monoclonal anti-fH antibody (Clone
90X, Quidel Inc) recognizes an epitope in the SCR1 of fH.
To study C3b binding, recombinant fH fragments (F4, F3, F2,
or F1,30 nM each) were incubated with C3b (70 nM). C3b
bound proteins were immunoprecipitated using anti-C3
antibody (10 µg) and protein A/G beads (20 µl) and
immunoblotted using an anti-fH antibody.
Cofactor activity
The effect of recombinant fH fragments on factor I-mediated
cleavage of C3b was studied by incubating 0.8 µM of plasma-
purified fH, recombinant F1, F2, F3, or F4 with 0.7 µM of C3b
and 0.5 µM of plasma-purified factor I at 37°C for 2 hours. The
products of C3b cleavage were separated by SDS-PAGE
under reducing conditions. Proteins were transferred to
membranes, immunoblotted with anti-C3 antibody, and
visualized by chemiluminescence.
Biacore analysis
Surface Plasmon Resonance (SPR)-based Biacore binding
experiments were performed at 25oC on a Biacore 3000 (GE
Healthcare). Plasma-purified VWF, recombinant VWF-A1,
VWF-A2 or VWF-A3 were immobilized on a CM3 or CM5
sensor chip using amine coupling procedure as recommended
by the manufacturer. Briefly, the ligand was diluted in sodium
acetate buffer as follows: 40 nM of VWF in 100 mM acetate
(pH 5.5), 200 nM of VWF-A1 in 10 mM sodium acetate (pH
5.5), 200 nM of VWF-A2 in 100 mM acetate (pH 5.5), and 200
nM of VWF-A3 in 10 mM acetate (pH 5.5). Following activation
of the sensor surface, the protein solution was injected (5 µL/
min) and coupled to the surface. The immobilization procedure
resulted in a surface density of 2100 RU for VWF, 1500 RU for
VWF-A1, 1000 RU for VWF-A2, and 800 RU for VWF-A3. A
reference surface with no protein coupled was used as a
control. In some experiments, an ovalbumin-coated surface
(500 RU) was used as a negative control. HEPES-buffered
saline (HBS: 10 mM HEPES, pH 7.3, 150 mM NaCl) was used
as running buffer. Plasma purified fH, recombinant full-length,
or truncated fH was injected over surface-immobilized ligands,
in the presence or absence of different divalent cations. After
completion of association and dissociation studies, bound
proteins were removed by two-minute injection of HBS
containing 3 mM EDTA to regenerate the ligand surface.
Baseline-corrected SPR response curves (with buffer blank
runs further subtracted) were used for data analysis.
Responses at equilibrium of the SPR curves were fitted to a
one-site binding (hyperbola) isotherm (GraphPad Prism 4) to
obtain equilibrium dissociation constant (KD). Non-equilibrium
data were globally fitted to pre-defined two-state model using
BIAevaluation software (Version 4.1). A control experiment was
also performed to detect a possible conformational change
(linked reaction) during binding of fH to its ligands. In this
experiment, 0.5 µM of fH in binding buffer (HBS containing 50
µM of ZnCl2) was injected to the ligand surface and allowed to
contact for a short (1 min) or a long period of time (4 min). The
association rate constant (ka1) and dissociation rate constant
(kd1) for the binding step, as well as forward rate constant (ka2)
and backward rate constant (kd2) for the conformational change
step were derived from global fitting of the SPR response
curve. The apparent dissociation constant (KDapp) was
calculated according to the formula KD = 1/((ka1/kd1) * (1+ka2/
kd2)).
ELISA assay
Plasma-purified factor H (30 nM) was coated on a 96-well
ELISA plate (50 µl each well) at 4oC overnight. The coated well
was blocked with 1% bovine serum albumin (BSA) for 1 hour at
room temperature and washed with PBST. Recombinant VWF-
A1 (200 nM), VWF-A2 (200 nM), VWF-A3 (200 nM), PBS
alone, or VWF (5 µg/ml) was incubated on immobilized fH (50
µl each well) for 2 hours at room temperature. In some
experiments, ristocetin (0.5 mg/ml) was included in the
incubation mixture. Following three washes with PBS-T, the fH-
bound His-tagged VWF A1, VWF A2, or VWF A3 was detected
using a primary anti-His (Penta-His, Qiagen) and secondary
HRP-conjugated antibodies in a microplate reader (BioTek) at
450 nm. The fH-bound VWF was detected using a primary anti-
VWF and secondary HRP-conjugated antibodies.
Depleting serum of Factor H or C3
Two hours after preincubation with 50 µl of protein A/G
beads, 250 µl of normal pooled serum was centrifuged at
10,000 × g for 10 min. The collected serum supernatant was
incubated with either 50 µl of polyclonal anti-fH or anti-C3
antibody (complement Technology Inc.) and protein A/G beads
for 2 hours at room temperature, and centrifuged to obtain
supernatant. C3-depleted serum sample was used as a control
for fH-depleted serum in our studies, because fH depletion
results in activation of the alternative complement system in
few minutes and in a rapid decline in C3 concentration in
serum.
Cleavage of FRETS-VWF73 by ADAMTS-13 in the
presence of fH
ADAMTS-13 activity was determined by measuring the rate
of cleavage of a fluorogenic substrate that contains 73 amino
acids of the A2 domain of VWF (FRETS-VWF73) (Gen-Probe)
according to the manufacturer’s protocol. The cleavage
reaction in 50 µl of substrate dilution buffer together with 50 µl
of test samples (10 nM of ADAMTS-13; 0, 0.4, 0.8, 1.6 µM of
fH) was induced by incubation for 30 minutes at room
temperature and recorded in a fluorescence reader (BioTek) at
excitation and emission wavelengths of 340 nm and 450 nm,
respectively. In some of the samples, 100 nM of polyclonal
anti-fH antibody was added. Fluorescence measured at time
zero (beginning of incubation) was subtracted from values
measured after 30 minutes of incubation. ADAMTS-13 activity
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was determined using a calibration curve based on calibrator
standards (Gen-Probe). In another group of experiments, 5 µl
of fH- or C3-depleted serum was used to cleave FRETS-
VWF73.
For kinetic studies, different concentrations of FRETS-
VWF73 (0.5, 1, 2, and 4 µM) were incubated with fixed
concentrations of recombinant ADAMTS-13 (10 nM) and fH
(0.66 µM) for 30 min at 37oC. The Vmax. was determined by
standard calibrator with 100% substrate cleavage activity
provided in Gen-Probe kit, and this was used for determining
the relative rate of substrate cleavage activity in each sample.
The collected data were fitted into a Michaelis-Menten
equation, and Vmax., Km, and kcat. were determined by
Lineweaver-Burk plot.
Cleavage of recombinant VWF-A2 by ADAMTS-13 in the
presence of fH
We measured the cleavage of recombinant GST-VWF-A2
fusion protein (100 nM) by recombinant ADAMTS-13 (10 nM) in
the presence or absence of plasma purified fH (0.6 µM) or
recombinant fH (100 nM) in 25 µl of cleavage buffer (100 mM
Tris-HCl, pH 8.5, 4 mM CaCl2, 0.02% Brij-35) at 37oC.
Reactions were quenched by adding reduced sample buffer,
and cleaved VWF-A2 was separated by SDS-PAGE on 10%
gels and detected by rabbit anti-VWF antibody. The rate of
cleavage was quantified by densitometry using NIH ImageJ
software (rsb. Info.nih.gov/nih-image). For kinetic studies, we
compared the cleavage of VWF-A2 by ADAMTS-13 (10 nM) in
the presence or absence of fH (0.6 µM) at different incubation
intervals (20 min to 2 hrs) to determine the half-maximal
cleavage time.
HUVEC Culture
The formation of VWF strings anchored to the surface of
activated HUVECs was measured under flow conditions as
previously described [22]. Briefly, endothelial cells were
obtained from human umbilical veins (HUVEC) under a
protocol approved by the Institutional Review Board of the
Baylor College of Medicine. The umbilical cords were washed
with phosphate buffer (140 mM NaCl, 0.4 mM KCl, 1.3 mM
NaH2PO4, 1.0 mM Na2HPO4, 0.2% glucose, pH 7.4), and then
infused with a collagenase solution (0.02%, Invitrogen Life
Technologies, Carlsbad, CA). After 30 min incubation at room
temperature, the cords were rinsed with 100 ml of the
phosphate buffer. Elutes from collagenase-treated umbilical
cords were centrifuged at 250 × g for 10 min. The cell pellets
were resuspended in Medium 199 (Invitrogen Life
Technologies) containing 20% heat-inactivated fetal calf serum
and 0.2 mM of L-glutamine, and plated on a culture dish coated
with 1% gelatin until confluent.
Parallel-plate flow chamber
HUVECs growing in a 35-mm cell culture dish were
stimulated with 25 µM histamine (Sigma-Aldrich, St. Louis, MO)
for 10 min at room temperature and then assembled to form
the bottom of the parallel-plate flow chamber (Glycotech,
Rockville, MD). The assembled chamber was mounted onto an
inverted-stage microscope (Nikon, Eclipse TE300, Garden City,
NY) and connected to a syringe pump to draw the Tyrode’s
buffer containing washed platelets through the chamber at 2.5
dyn/cm2 shear stress. The chamber system was kept at 37oC
with a thermostatic air bath during the experiments. Acquired
images were analyzed offline using MetaMorph software
(Universal Images, West Chester, PA).
Cleavage of ultra-large (UL) VWF under flow conditions
by ADAMTS-13 in the presence of fH (string Assay)
We measured the cleavage of ULVWF-platelet strings
formed on endothelial cells in a parallel platelet chamber as
described above. Briefly, HUVECs were stimulated with 25 µM
histamine (Sigma Aldrich, St. Louis, MO) for 3 min and then
perfused with washed platelets in the presence of recombinant
ADAMTS-13 (10 nM, control), ADAMTS-13 with fH (1.3 µM), or
ADAMTS-13, factor H, and anti-fH antibody (100 nM) through
the parallel-plate flow chamber. The number of platelet-
decorated ULVWF strings (20 continuous review fields at 200
x) was counted at 10 S and 2 min time points after perfusion
began. ADAMTS-13 activity was defined as the percent
reduction of ULVWF strings compared to negative controls of
buffer perfusion alone [22].
Statistics
Data are presented as mean ± SD. Comparisons were made
using Student’s t test and ANOVA; p < 0.05 was considered to
be statistically significant.
Results
Factor H binds to VWF
To detect binding of fH to VWF, we coincubated purified
VWF and fH in PBS buffer and immunoprecipitated VWF using
resin beads coated with anti-VWF antibody. Factor H was
detected to coprecipitate with VWF (Figure 1A). We also
investigated the association between fH and VWF in serum by
studying the proteins co-immunoprecipitated with VWF, and
found that fH coprecipitated with VWF in normal serum (Figure
1B); however, we could not determine the extent of this
association in serum and determine the fraction of VWF binds
to fH in vivo. Binding of fH to VWF was enhanced in the
presence of ristocetin (Figure 1C). To study the kinetics of the
interaction between fH and VWF, we used SPR-based Biacore
assay. Binding of full-length fH to immobilized VWF and
subsequent dissociation of bound fH were detected as SPR
response curve in real time under flow conditions. To identify
the correct model for analysis of the binding data, we
compared the dissociation phase of the long injection (3 or 4
min) of fH over its ligands with that of the short injection (1 or 2
min) (Figure 1C). The long injection had a slower dissociation
than the short injection, indicating a linked reaction during fH
interaction with VWF involving conformational changes. Based
on these observations, the two state conformational change
model was used to fit the sensorgrams and to obtain binding
kinetics (Figure 1D). This model describes a 1:1 binding of
analyte (fH) to immobilized ligand (VWF or its fragments)
followed by a conformational change in the complex. The result
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showed that a conformational change was involved during the
interaction. The association rate constant [ka1 = 6.0 ± 0.10 (x104
1/Ms)], dissociation rate constant [kd1 = 1.58 ± 0.06 (x 10-2 1/s)],
forward rate constant [ka2 = 7.0 ± 0.14 (x 10-3 1/s)], and
backward rate constant [kd2 = 9.0 ± 0.17 (x 10-4 1/s)] were
derived from global fitting of SPR response curves (Figure 1D)
and the apparent dissociation constant KDapp of 32.9 ± 8.0 nM
was determined. This binding affinity was based on the
interaction between fH and the surface immobilized VWF, but
we could not determine the affinity of this interaction in serum.
The effect of different divalent cations (Zn, Ca, Mg, Mn, and
Ba) on the interaction between fH and VWF was studied by
conducting SPR studies using binding buffer containing these
cations. Inclusion of ZnCl2 in the binding buffer increased the
binding of fH to VWF (Figure 1E). Even though there was a
detectable level of fH bound to VWF in the presence of other
divalent cations (MnCl2, CaCl2, BaCl2, and MgCl2), this amount
was only 10% of that in the presence of zinc.
Binding site of fH on VWF
We used ELISA to detect the binding of recombinant VWF-A
domains to immobilized fH, and identified binding of VWF-A1
and -A2 domains, but not the VWF-A3 domain, to fH (Figure
2A). To confirm these results, we examined
coimmunoprecipitation of fH with recombinant His-tagged
VWF-A domains. Factor H coprecipitated with VWF-A1 and
VWF-A2 (produced by E. coli or mammalian cells) domains but
not with the VWF-A3 domain or VWF-BC domains (Figure 2B
and 2C). In addition to ELISA and immunoprecipitation, we
used SPR to study the binding of fH to VWF-A domains. Factor
H was found to bind to immobilized VWF-A1 and -A2 domains;
however, binding responses of fH to VWF-A3 were negligible
(Figure 2D). Similar to VWF, VWF-A1 domain could also trigger
a conformational change in the complex, with similar rate
constants (ka1 = 5.36 x104 1/Ms, kd1 = 3.58 x 10-2 1/s, ka2 = 7.97
x 10-3 1/s, except a faster kd2 (2.54 x 10-3 1/s) which contributed
to a weaker affinity (KDapp = 161 nM). The SPR profiles for fH
binding to VWF-A2 were different compared to VWF or VWF-
A1; the binding reached equilibrium and could be fitted to a
one-site binding isotherm (Figure 2D inset) to obtain
equilibrium dissociation constant (KD =147 nM).
Generating recombinant full-length and truncated fH
molecules
To identify the region in fH involved in its binding to VWF, we
generated recombinant full-length and truncated fH molecules.
F4 (includes all 20 SCRs), F3 (SCR1-15), F2 (SCR1-10), and
F1 (SCR1-5) are depicted in Figure 3A. The wild type and
mutant cDNAs encoding full-length and truncated fH were
subcloned into an eukaryotic expression vector and transfected
in HEK 293 cell line. The purified expressed proteins are
shown after Western-blotting with anti-fH antibody (Figure 3B)
and after Coomasie blue staining of the SDS-polyacrylamide
gel (Figure 3C). We investigated the structural and functional
integrity of the recombinant fH fragments (F1, F2, F3, and F4)
by studying their binding to C3b and their Factor I-cofactor
activity. All fH recombinant fragments (F1, F2, F3, and F4)
contained SCR1-4 and were able to bind to C3b (Figure 3D)
and enhanced cleavage of C3b by factor I (Figure 3E).
Binding site of VWF on fH
We compared the binding of recombinant VWF-A2 and
VWF-A1 to full-length and truncated fH molecules, using a co-
immunoprecipitation assay. After incubation with fH molecules,
the recombinant VWF-A2 domain (GST-A2 fusion protein) was
precipitated using glutathione-conjugated agarose beads.
Western blotting with polyclonal anti-fH antibody (Figure 4A)
and monoclonal anti-fH antibody recognizing SR1 (Figure 4B)
revealed full-length fH (F4) coprecipitating with VWF-A2.
Subsequent removal of C-terminal SCRs, F3 (SCR1-15) and
F2 (SCR1-10) resulted in a decrease in binding to VWF-A2
compared to full-length fH (F4 with SCR1-20). F1 (SCR1-5) did
not bind to VWF-A2 and was not detected among
coprecipitated proteins (Figure 4A-B). Immunoprecipitation
studies using VWF-A1 and recombinant fH fragments showed
that shorter fH fragments (F1 and F2) bound less than longer
fragments (F3 and F4) to VWF-A1. These results were
consistent with binding of VWF-A1 to SCR10-20 on fH (Figure
4C). To further investigate the binding site of VWF on fH, we
used SPR to compare binding of the full-length recombinant fH
(F4) to VWF-A2 and VWF with those of truncated fH molecules
(F1, F2, and F3). Full-length factor H bound to VWF and VWF-
A2 more than truncated fH molecules (Figure 4D). Progressive
truncation of fH from the C-terminus resulted in a decrease in
binding to VWF-A2 and VWF, so that F1 (SCR1-5) did not
show binding to VWF or VWF-A2. Furthermore, in comparing
the binding profiles, F1 showed the least stable binding to VWF
and VWF–A2 domain, indicated by the fast and complete
dissociation of the complex; While full-length fH dissociated
slower and remained bound on the chip surface. Binding to
ovalbumin served as a negative control and was negligible
(Figure 4E).
Factor H enhances cleavage of VWF
Cleavage of recombinant VWF-A2 domain after incubation
with recombinant ADAMTS-13 was detected by Western-
blotting using anti-VWF antibody (Figure 5A). Addition of
plasma-purified fH enhanced the cleavage of VWF-A2 by
ADAMTS-13 as evident by an increase in the density of
cleavage bands. While ADAMTS-13 alone cleaved 46 ± 4% of
the VWF-A2 in 60 min; the presence of fH increased the
efficiency of cleavage of VWF-A2 to 84 ± 5%, respectively
(Figure 5B). For kinetic analyses, we measured the effect of a
constant concentration of fH on the cleavage of VWF-A2 at
different time points after incubation with ADAMTS-13 (15 min,
30 min, 1 hr, 2 hr, 3 hr, and 4hr), using Western-blotting (Figure
5C). The cumulative results of three separate experiments
were summarized in Figure 5D, showing that half-maximal
cleavage of VWF-A2 was completed in about 13 min in the
presence of fH, compared to about 22 min in the absence of
fH. To quantify the effect of fH on ADAMTS-13-mediated VWF
cleavage, we measured the activity of recombinant
ADAMTS-13 in the presence or absence of plasma-purified fH
using FRETS-VWF73 as substrate in a commercial kit
(ATS-13, Gen-Probe). Cleavage of the substrate was
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Figure 1.  Factor H binds to VWF.  (A) Purified VWF (20 nM) was incubated with different concentrations of fH (30, 60 nM) and
immunoprecipitated (IP) using anti-VWF antibody or control IgG. VWF co-precipitated proteins were immunoblotted using anti-fH
antibody. (B) Proteins immunoprecipitated from normal human serum using anti-VWF antibody or control antibody was
immunoblotted (IB) using anti-fH (upper panel) or anti-VWF antibody (lower panel). A representative blot is shown (n=4). (C) Binding
of plasma-purified VWF (5 µg/ml) to immobilized fH (30 nM) was studied using ELISA. The results are shown as mean with standard
deviation (n=4, p<0.02). (D) Dissociation profiles for the fH/VWF interaction using long (solid line) or short (dashed line) injection
time of fH (1 µM). Slower dissociation of fH from VWF with a long injection indicated that a conformational change could be involved
during binding. (E) In a Biacore assay, two-fold increasing concentration (5 to 320 nM) of fH in HBS containing 50 µM ZnCl2 were
injected over immobilized VWF (40 nM) at a flow rate of 30 µL/min. Baseline corrected SPR response curves (shown in black, with
lower curve corresponding to lower concentration of fH injected) were globally fitted to the predefined two-state model. The fitted
curves are shown in red and the dissociation constant KDapp of 33 nM was obtained from the fit. (F) To study the effect of different
cations on binding of fH to VWF, 0.5 µM fH was injected onto the VWF in the presence of HBS running buffer containing ZnCl2 (0.1
mM), CaCl2 (2 mM), BaCl2 (1 mM), MnCl2 (1 mM), MgCl2 (1 mM), or EDTA (3 mM).
doi: 10.1371/journal.pone.0073715.g001
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Figure 2.  Factor H binds to VWF-A1 and –A2 domains.  (A) Binding of recombinant fragments of VWF (A1, A2, A3, 200 nM
each) to immobilized fH (30 nM) was studied using ELISA. The results are shown as mean with standard deviation (n=3, t-test). (B)
Recombinant His-tagged VWF-A1, –A2, or –A3 domain (100 nM) was incubated with purified fH (30 nM) and immunoprecipitated
(IP) by anti-fH antibody or IgG. Co-precipitated proteins were immunoblotted (IB) with anti-VWF antibody. A representative blot is
shown (n=3). (C) Recombinant His-tagged VWF-A2 (100 nM) and Myc-tagged VWF-BC domains (100 nM), both purified from
transfected HEK 293 cells, were incubated with purified fH (30 nM), precipitated with anti-fH antibody or IgG, separated by SDS-
PAGE, and transferred to immobilon-P membranes. The same membrane was blotted with anti-VWF (upper panel) or anti-fH
antibody (lower panel). (D) In a Biacore assay, two-fold increasing concentration (40 to 640 nM) of fH were injected over
immobilized VWF-A1, VWF-A2, or VWF-A3 (200 nM each) at a flow rate of 20 µL/min. Baseline corrected SPR response curves are
shown in black, with lower curve corresponding to lower concentration of fH injected. The sensorgrams for fH binding to VWF-A1
were fitted to the predefined two-state model (fitted curves are shown in red). For fH to VWF-A2 binding interaction, the responses
at equilibrium of the SPR curves were fitted to a one-site binding isotherm (inset) to obtain the equilibrium dissociation constant (KD).
Binding of fH to VWF-A3 was negligible.
doi: 10.1371/journal.pone.0073715.g002
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Figure 3.  Recombinant full-length and truncated Factor H.  (A) Schematic representation of fH structure that includes 20 SCR
domains and design of recombinant fH molecules used in our experiments. Amino acid lengths and SCR domains of each
recombinant fragment are shown. (B) Immunoblotting (IB) of purified recombinant full-length and truncated fH molecules using
polyclonal anti-fH antibody. (C) Purified recombinant full-length and truncated fH molecules were detected after PAGE (10%) and
Coomassie blue staining. (D) C3b was incubated with plasma purified and recombinant fH molecules and immunoprecipitated using
polyclonal anti-C3 antibody. Precipitated proteins were immunoblotted using anti-fH antibody. (E) Cofactor activity of plasma purified
and recombinant fH molecules was investigated by incubating them with purified C3b and factor I. Factor I-mediated cleavage of
C3b generated two cleavage products (arrowheads) originated form C3b α chain.
doi: 10.1371/journal.pone.0073715.g003
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Figure 4.  Binding of recombinant full-length and truncated fH molecules to VWF and VWF-A2.  (A) Recombinant GST VWF-
A2 protein (100 nM) was mixed with recombinant full-length or truncated fH (30 nM) and precipitated using glutathione agarose
beads. The precipitated proteins were immunoblotted (IB) with anti-fH antibody for examining the association between VWF-A2 and
fH molecules. Immunoblotting with anti-VWF antibody served as loading control. A representative blot is shown (n=3). (B) We
repeated the above experiment but used a monoclonal anti-fH antibody (clone 90X) recognizing SCR1 to immunoblot fH fragments
precipitated with GST-VWF-A2. (C) Recombinant VWF-A1 protein (100 nM) was mixed with recombinant full-length or truncated fH
(30 nM) and precipitated using polyclonal anti-VWF antibody. The precipitated proteins were immunoblotted with monoclonal anti-fH
antibody (clone 90X) for examining the association between VWF-A1 and fH molecules. (D) SPR sensograms were generated by
injecting recombinant fH proteins (F1, F2, F3, or F4) at a concentration of 10 µg/ml over immobilized VWF-A2 or VWF for 60s
followed by dissociation for 2 min. (E) SPR sensograms generated by injecting fH proteins (F1, F2, F3, and F4) over immobilized
ovalbumin (OVA), served as a negative control.
doi: 10.1371/journal.pone.0073715.g004
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measured in a fluorometer after 30 min of incubation with
recombinant ADAMTS-13. As shown in Figure 6A, plasma-
purified fH increased the cleavage of FRETS-VWF73 by
recombinant ADAMTS-13 from 36 ± 15% to 79 ± 1% with the
effect reaching a plateau at an fH concentration of 0.4µM.
Factor H enhancement of ADAMTS-13 activity was completely
reversed after the addition of polyclonal anti-fH antibody
(Figure 6A). Polyclonal anti-fH antibody alone did not affect
ADAMTS-13 activity (data not shown).
We also measured ADAMTS-13 activity in fH-depleted
serum. Removal of fH by immunoadsorption (using sepharsoe
beads coated with an anti-fH antibody) (Figure 6B) resulted in a
62% reduction in cleavage of FRETS-VWF73 as compared to
that in C3-depleted serum (n=3, Data not shown). C3-depleted
serum was also prepared by immunoadsorption and served as
a control because fH-depletion rapidly results in consumption
of serum C3.
We used different concentrations of FRETS-VWF73
substrate to identify the effect of fH on ADAMTS-13 kinetics.
We found that the presence of fH enhanced ADAMTS-13-
mediated cleavage of FRETS VWF73 by 2.34 folds (Kcat/Km
ratio of 164 S-1nM-1 in the presence of fH and 70.2 S-1nM-1 in
the absence of fH, Table 1).
We then determined whether factor H affected the cleavage
of ULVWF strings under flow conditions. Counting the number
of strings after 2 min of perfusion showed that the rate of
ULVWF cleavage was comparable in the presence or absence
of factor H (Figure 6C). However, counting the strings after a
shorter perfusion interval (began string counting 10 sec after
perfusion started) revealed that factor H significantly
accelerated cleavage of ULVWF, an effect that was blocked by
preincubation of factor H with a polyclonal Factor H antibody.
Full-length fH enhances ADAMTS-13 function
We compared the effect of full-length and truncated fH
molecules on ADAMTS-13-mediated cleavage of VWF-A2
(Figure 7A). Removal of C-terminal SCRs progressively
resulted in a decrease in the fH enhancement of VWF-A2
cleavage. F3 (lacking SCRs 15-20) showed reduced
enhancement of cleavage compared to the full-length fH (F4)
molecule, while F2 and F1 (missing SCRs 10-20 and 5-20,
respectively) showed no enhancement of cleavage (Figure 7B).
Discussion
Factor H binds to glycosoaminoglycans on the cell
membrane and protects cells against complement-induced
damage. It binds to several other ligands, including heparin,
C3b, integrins αvβ3 and αIIbβ3, and C-reactive protein [23–26],
but the functional consequences of these protein–protein
interactions are not clear. In this study, we identified VWF as
an additional protein partner for fH. We demonstrated a high
affinity interaction (KDapp ~ 33 nM) between these two
multidomain proteins. This is a high affinity and one would
predict that all VWF multimers circulating in the blood are fH-
bound. However, this is unlikely to be the case for three
reasons. First, binding affinities were calculated from the
binding of fH to either immobilized VWF multimers or
recombinant A1 and A2 domains in vitro. In both experimental
conditions, the A1 and A2 domains are exposed and readily
available for fH to bind to. Normally, both domains are buried in
the tertiary structure of circulation VWF multimers, inaccessible
to fH. Therefore, the amount of circulating VWF multimers that
is fH-bound is expected to be small in a non-disease state. This
notion is supported by the report by Hulstein et al. [27] that a
nanobody made against the VWF A1 detected a very small
amount of VWF in blood samples from healthy subjects, but a
significantly increased amount of VWF in patients with TTP. It
is also supported by our finding that the VWF-fH interaction
was enhanced in the presence of ristocetin, which is known to
induce an active conformation of VWF [21,28]; and is
consistent with a recent report by Turner et al., who showed
binding of fH to ULVWF strings secreted by, and anchored to,
endothelial cells [29]. Second, VWF exists in the blood as
multimers of different sizes and a calculated binding affinity for
such a heterogeneous ligand may be accurate only for VWF of
a particular size. Finally, in our studies binding affinities were
measured with purified proteins without likely interferences
from other plasma proteins.
We showed that fH binding to VWF increases ADAMTS-13-
mediated cleavage of VWF-A2. This might be due to a
conformational change in VWF induced by binding of fH to
VWF-A2 that makes the cleavage site more accessible to
ADAMTS-13. In order to identify the region(s) of fH involved in
its binding to VWF, we generated recombinant full-length and
truncated fH molecules. Removal of C-terminal SCRs
decreased binding of fH to VWF. Progressive truncations of fH
C-terminal SCRs progressively diminished its binding to VWF
and VWF-A2, until fH truncated of its 15 C-terminal SCRs
(SCR 1-5 intact) was finally unable to bind to VWF and VWF-
A2. The decrease in binding of truncated fH to VWF was
associated with a decrease in its effect on ADAMTS-13-
mediated cleavage of VWF-A2. The presence of SCRs 15-20
in fH was important for its cofactor role in VWF cleavage, and
fH fragments without this region (F3, F2, and F1) had less
effect on ADAMTS-13-mediated VWF-A2 cleavage. In fact,
removal of SCRs 10-20 caused a complete elimination of fH’s
effect on VWF-A2 cleavage. Together, these results suggest
that fH modifies VWF cleavage primarily by binding and by
potentially making VWF more accessible to ADAMTS-13.
This functional interaction between fH, VWF and
ADAMTS-13 could contribute to the pathogenesis of thrombotic
microangiopathy in both TTP and aHUS and provide a
mechanistic basis for the frequently observed clinical overlap
between TTP and HUS. Mutations in fH are the most common
genetic alteration detected in patients with aHUS [9,30] and
Table 1. Kinetic Cleavage of FRETS-VWF73 by
ADAMTS-13 in the presence or absence of fH.
  Km(μM) kcat. (s-1)
kcat./km
(s-1nM) Fold change
ADAMTS-13 5.86 ± 0.94 0.412 ± 0.04 70.2 1.00
ADAMTS-13+ Factor H 12.51 ± 3.78 2.056 ± 0.11 164.4 2.34
The data are expressed as means + SD (n=3).
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Figure 5.  Factor H enhances ADAMTS-13-mediated cleavage of recombinant VWF-A2.  (A) Cleavage of VWF-A2 (100 nM) by
ADAMTS-13 (10 nM) after 1 hr incubation in the presence or absence of fH (0.6 µM) was detected by immunoblotting (IB) with
polyclonal anti-VWF antibody. A representative blot is shown (n=5). (B) The results of three separate experiments with
ADAMTS-13-mediated VWF-A2 cleavage were summarized as bar graphs. The VWF-A2 cleavage (%) was calculated by
measuring the ratio of band density of cleaved to uncleaved + cleaved VWF-A2. (C) Recombinant GST VWF-A2 (100 nM) was
incubated with ADAMTS-13 (10 nM), in the presence or absence of fH (0.6 µM) for different time intervals. The cleavage products
were detected by immunoblotting with anti-GST antibody. A representative blot is shown (n=3). (D) The half maximal cleavage time
of GST VWF-A2 by ADAMTS-13 was calculated using the data obtained from different incubation intervals (20 minutes to 2 hours),
in the presence or absence of fH. The results of these experiments were summarized as a linear graph (n=3, t-test, ** p<0.01, *
p<0.05).
doi: 10.1371/journal.pone.0073715.g005
Factor H Binds to VWF
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e73715
Figure 6.  Factor H enhances ADAMTS-13-mediated cleavage of recombinant FRETS-VWF73 and ULVWF.  (A) Cleavage of
ADAMTS-13 substrate (FRETS-VWF73) at different concentrations of fH was quantified using a commercial kit (ATS-13, Gen-
Probe). Polyclonal anti-fH antibody (100 nM) was used to block the effect of fH on ADAMTS-13-mediated cleavage of the substrate
(n=3). (B) Factor H was removed from normal serum by immunoadsorption using sepharose beads coated with polyclonal anti-fH
antibody. Immunoblotting of 1 µl of fH-depleted serum with an anti-fH antibody showed the absence of fH band in comparison to
normal serum. (C) The number of ULVWF strings anchored to the surface of histamine-stimulated-HUVECs (with adherent
platelets) in the presence of recombinant ADAMTS-13 (control); ADAMTS-13 and factor H; or ADAMTS-13, factor H and a
polyclonal anti-factor H antibody was counted starting at 10 sec or 2 min after perfusion in 20 review fields (×200 magnifications;
n=4, *p<0.05).
doi: 10.1371/journal.pone.0073715.g006
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most of these mutations are located in SCRs 18-20,
encompassing the region of fH directing cell surface binding
[5–8,10]. The mechanism of thrombotic microangiopathy in
aHUS is not known, but is probably related to complement-
induced damage resulting from lack of negative regulation of
the complement system. Four observations provide evidence in
support of this concept. First, mutations in other complement
regulatory proteins such as CD46 or factor I cause aHUS
[30,31]. Second, aHUS developed in fH deficient mice only
after restoration of normal plasma C3 concentrations by the
Figure 7.  The effect of recombinant full-length and truncated fH on ADAMTS-13-mediated cleavage of VWF-A2.  (A)
Cleavage of recombinant VWF-A2 (100 nM) after 30 minutes of incubation with ADAMTS-13 (10 nM) in the presence or absence of
full-length or truncated fH (100 nM) was studied by Western-blotting using anti-GST antibody. A representative blot is shown (n=7).
(B) The band intensity of the VWF-A2 cleavage products was compared between samples with full-length and truncated fH (n=7, t-
test).
doi: 10.1371/journal.pone.0073715.g007
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transgenic expression of truncated fH molecule (SCRs 1-15),
which is capable of modulating complement activation in
plasma but not on cell surfaces [14]. Third, in this transgenic
mouse model, aHUS could be reversed when C5 deficiency
was induced [32]. Four, inhibition of the complement system
using a monoclonal anti-C5 antibody (Eculizumab, Alexion
Pharmaceuticals) was successful in treating patients with
aHUS [33–35].
Our data introduce the hypothesis that fH may contribute to
clinical thrombotic microangiopathies through a complement-
independent mechanism. We demonstrated that full-length fH
enhances cleavage of VWF-A2 by ADAMTS-13 while fH
molecules truncated of regions affected by aHUS-inducing
mutations lose this capacity. This hypothesis is consistent with
reports that ADAMTS-13 activity was significantly lower in the
acute phase of recurrent or familial HUS [15,16].
In TTP, deficiency in ADAMTS-13 function is the main
etiologic factor. However, reports of some patients with a
clinical diagnosis of TTP without severe ADAMTS-13
deficiency [36], and the presence of a few individuals with
severe ADAMTS-13 deficiency who either do not develop TTP
or do so only later in life [37,38], suggest that other molecules
(as co-factors) may be involved in the pathogenesis of TTP.
We speculate that low levels of fH act as a cofactor to
ADAMTS-13 deficiency in the pathogenesis of TTP.
In conclusion, we have shown that fH binds to VWF and
enhances its cleavage by ADAMTS-13. This interaction could
be a component in the pathogenesis of aHUS and it provides a
mechanistic link between the pathophysiology and clinical
manifestations of thrombotic microangiopathies [39]. Further
work to characterize the structural and functional elements
directing this interaction should elucidate molecular
mechanisms of the thrombotic microangiopathic syndromes
and could provide new approaches to the diagnosis and
treatment of these dangerous diseases.
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